Navigating the Misdiagnosis of Pityriasis Rubra Pilaris and Successful Treatment With Guselkumab: A Case Report of Dual Biologic Therapy

Pityriasis rubra pilaris (PRP) is a rare and chronic dermatologic condition often misdiagnosed due to its clinical resemblance to psoriasis. It significantly impacts quality of life due to its clinical presentation and systemic discomfort. Conventional treatments, including retinoids, corticosteroids, and methotrexate, often yield suboptimal outcomes, particularly in refractory cases. Recently, biologic therapies have shown promise for PRP management. This case report describes the successful treatment of PRP with guselkumab. A 57-year-old male presented with an eight-year history of refractory papulosquamous disorder affecting 70% of his body surface area, initially diagnosed and treated as psoriasis. The patient had failed topical steroids, topical calcineurin inhibitors, sulfasalazine, and methotrexate. He had a past medical history of asthma treated with dupilumab. On skin exam, there were orange-red scaly plaques on the scalp, trunk, upper and lower extremities, buttocks, and genitals. Some of the plaques coalesced in areas to confluence, making PRP a presumptive diagnosis. Diagnosis was confirmed by three punch biopsies, and treatment with guselkumab 100mg subcutaneous injection was initiated. The patient noted improvement after the first loading dose and achieved complete skin clearance following the second dose four weeks later. At his one-year follow-up, he maintained full clearance while receiving guselkumab 100 mg subcutaneously every eight weeks. This case highlights the potential of guselkumab as an effective treatment for refractory PRP, even in cases of extensive disease. It underscores the importance of accurate diagnosis through biopsy and demonstrates the feasibility of concurrent biologic therapies for managing comorbid inflammatory conditions. Further research is needed to optimize biologic treatment strategies and enhance understanding of dual biologic use in complex dermatologic cases.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2025-12-01
DOI
https://doi.org/10.7759/cureus.98267
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Navigating the Misdiagnosis of Pityriasis Rubra Pilaris and Successful Treatment With Guselkumab: A Case Report of Dual Biologic Therapy

Sylvia Martinez-Cabriales, Danika Bongfeldt
Cureus
Psoriasis: Treatment and Pathogenesis
article

Navigating the Misdiagnosis of Pityriasis Rubra Pilaris and Successful Treatment With Guselkumab: A Case Report of Dual Biologic Therapy

Sylvia Martinez-Cabriales, Danika Bongfeldt
article en

Abstract

Pityriasis rubra pilaris (PRP) is a rare and chronic dermatologic condition often misdiagnosed due to its clinical resemblance to psoriasis. It significantly impacts quality of life due to its clinical presentation and systemic discomfort. Conventional treatments, including retinoids, corticosteroids, and methotrexate, often yield suboptimal outcomes, particularly in refractory cases. Recently, biologic therapies have shown promise for PRP management. This case report describes the successful treatment of PRP with guselkumab. A 57-year-old male presented with an eight-year history of refractory papulosquamous disorder affecting 70% of his body surface area, initially diagnosed and treated as psoriasis. The patient had failed topical steroids, topical calcineurin inhibitors, sulfasalazine, and methotrexate. He had a past medical history of asthma treated with dupilumab. On skin exam, there were orange-red scaly plaques on the scalp, trunk, upper and lower extremities, buttocks, and genitals. Some of the plaques coalesced in areas to confluence, making PRP a presumptive diagnosis. Diagnosis was confirmed by three punch biopsies, and treatment with guselkumab 100mg subcutaneous injection was initiated. The patient noted improvement after the first loading dose and achieved complete skin clearance following the second dose four weeks later. At his one-year follow-up, he maintained full clearance while receiving guselkumab 100 mg subcutaneously every eight weeks. This case highlights the potential of guselkumab as an effective treatment for refractory PRP, even in cases of extensive disease. It underscores the importance of accurate diagnosis through biopsy and demonstrates the feasibility of concurrent biologic therapies for managing comorbid inflammatory conditions. Further research is needed to optimize biologic treatment strategies and enhance understanding of dual biologic use in complex dermatologic cases.

CureusVol. 17(12)
NOSM University (CA)
Openalex Percentile: Top 57%
Psoriasis: Treatment and Pathogenesis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.